Nasdaq · CIK 0000887359
VCEL Vericel Corp
Insider trading from SEC Form 4. Last filing Aug 14, 2026. Close $40.62 on Oct 12, 2026, +38% from the 52-week low and -16% from the high.
In brief
Vericel Corp (VCEL) has 93 SEC Form 4 filings on file from 11 insiders, the latest filed on Aug 14, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $1.0M, net -$1.0M.
53 open-market trades have been scored at VCEL. The newest: Kevin F McLaughlin (director) sold $312k of stock on Aug 12, 2026, filed Aug 14, 2026, scored 19 (weak), under a 10b5-1 plan. The largest of the 50 shown: Dominick Colangelo (President and CEO) sold $2.4M on Mar 12, 2025, scored 35 (weak), under a 10b5-1 plan. 3 insiders sold within 14 days of each other around Aug 12, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Aug 12, 2026.
Last 90 days
Net insider value
-$1.0M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$1.0M by 3 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
VCELOct 12, 2026 · close 40.62
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Vericel Corp, scored: the newest 50 of 53.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Kevin F McLaughlin director sell | $312k 7,000 shares | -28% | +52% from low-7% from high | |
| 27Weak | Michael Halpin Chief Operating Officer sell | $468k 10,000 shares | -38% | +57% from low-5% from high | |
| 27Weak | Jonathan Siegal Principal Accounting Officer sell | $220k 4,500 shares | -175% | +62% from low-1% from high | |
| 36Weak | Sean C. Flynn Chief Legal Officer sell | $685k 15,000 shares | -90% | +58% from low0% from high | |
| 17Weak | Jonathan Mark Hopper Chief Medical Officer sell | $450k 10,000 shares | -12% | +58% from low0% from high | |
| 34Weak | Joseph Anthony Mara Jr Chief Financial Officer sell | $224k 5,000 shares | -24% | +58% from low0% from high | |
| 25Weak | Jonathan Siegal Principal Accounting Officer sell | $123k 2,732 shares | -244% | +58% from low0% from high | |
| 34Weak | Sean C. Flynn Chief Legal Officer sell | $603k 15,000 shares | -90% | +37% from low-7% from high | |
| 26Weak | Michael Halpin Chief Operating Officer sell | $402k 10,000 shares | -38% | +37% from low-7% from high | |
| 0Weak | Jonathan Mark Hopper Chief Medical Officer sell | $153k 4,375 shares | -5% | +17% from low-25% from high | |
| 18Weak | Kevin F McLaughlin director sell | $230k 7,000 shares | -32% | +12% from low-28% from high | |
| 55Moderate | Paul K Wotton director sell | $327k 10,000 shares | -35% | +12% from low-28% from high | |
| 34Weak | Joseph Anthony Mara Jr Chief Financial Officer sell | $203k 5,000 shares | -19% | +20% from low-23% from high | |
| 42Moderate | Jonathan Siegal Principal Accounting Officer sell | $188k 4,855 shares | -81% | +25% from low-20% from high | |
| 0Weak | Jonathan Mark Hopper Chief Medical Officer sell | $122k 3,472 shares | -4% | +16% from low-25% from high | |
| 16Weak | Heidi Hagen director sell | $486k 15,000 shares | -32% | +9% from low-32% from high | |
| 30Weak | Sean C. Flynn Chief Legal Officer sell | $754k 21,421 shares | -279% | +19% from low-31% from high | |
| 33Weak | Michael Halpin Chief Operating Officer sell | $364k 10,305 shares | -39% | +19% from low-31% from high | |
| 3Weak | Kevin F McLaughlin director sell | $243k 7,000 shares | -32% | +16% from low-40% from high | |
| 11Weak | Michael Halpin Chief Operating Officer sell | $405k 10,000 shares | -38% | +35% from low-35% from high | |
| 0Weak | Jonathan Mark Hopper Chief Medical Officer sell | $65k 1,652 shares | -2% | +26% from low-39% from high | |
| 40Moderate | Paul K Wotton director sell | $190k 5,000 shares | -16% | +26% from low-39% from high | |
| 8Weak | Michael Halpin Chief Operating Officer sell | $107k 2,642 shares | -14% | +38% from low-34% from high | |
| 11Weak | Kevin F McLaughlin director sell | $270k 7,000 shares | -32% | +31% from low-37% from high | |
| 17Weak | Michael Halpin Chief Operating Officer sell | $298k 7,358 shares | -32% | +30% from low-37% from high | |
| 0Weak | Jonathan Mark Hopper Chief Medical Officer sell | $358k 10,000 shares | -13% | 0% from low-44% from high | |
| 3Weak | Kevin F McLaughlin director sell | $251k 7,000 shares | -32% | +4% from low-41% from high | |
| 1Weak | Jonathan Mark Hopper Chief Medical Officer sell | $401k 10,000 shares | -13% | +7% from low-35% from high | |
| 28Weak | Dominick Colangelo President and CEO sell | $1.2M 28,125 shares | -10% | +12% from low-32% from high | |
| 12Weak | Kevin F McLaughlin director sell | $280k 7,000 shares | -32% | +7% from low-35% from high | |
| 20Weak | Dominick Colangelo President and CEO sell | $2.1M 49,700 shares | -17% | +15% from low-28% from high | |
| 35Weak | Dominick Colangelo President and CEO sell | $2.4M 53,183 shares | -19% | - | |
| 17Weak | Heidi Hagen director sell | $446k 9,000 shares | -24% | - | |
| 28Weak | Michael Halpin Chief Operating Officer sell | $495k 10,000 shares | -39% | - | |
| 18Weak | Jonathan Mark Hopper Chief Medical Officer sell | $495k 10,000 shares | -13% | - | |
| 24Weak | Sean C. Flynn Chief Legal Officer sell | $87k 1,669 shares | -69% | - | |
| 42Moderate | Sean C. Flynn Chief Legal Officer sell | $220k 3,835 shares | -84% | - | |
| 41Moderate | Paul K Wotton director sell | $153k 2,600 shares | -9% | - | |
| 19Weak | Jonathan Mark Hopper Chief Medical Officer sell | $587k 10,000 shares | -15% | - | |
| 6Weak | Robert L Zerbe Md director sell | $150k 2,500 shares | -9% | - | |
| 35Weak | Dominick Colangelo President and CEO sell | $1.9M 35,000 shares | -15% | - | |
| 21Weak | Kevin F McLaughlin director sell | $389k 7,000 shares | -37% | - | |
| 14Weak | Robert L Zerbe Md director sell | $281k 5,000 shares | -17% | - | |
| 28Weak | Dominick Colangelo President and CEO sell | $1.4M 35,000 shares | -15% | - | |
| 11Weak | Steven C Gilman director sell | $241k 5,833 shares | -35% | - | |
| 33Weak | Dominick Colangelo President and CEO sell | $854k 24,000 shares | -13% | +56% from low-9% from high | |
| 47Moderate | Sean C. Flynn SVP, General Counsel sell | $53k 1,538 shares | -26% | +56% from low-9% from high | |
| 47Moderate | Paul K Wotton director sell | $187k 5,000 shares | -16% | +62% from low-6% from high | |
| 33Weak | Dominick Colangelo President and CEO sell | $833k 24,397 shares | -13% | +48% from low-14% from high | |
| 40Moderate | Michael Halpin Chief Operating Officer sell | $618k 17,447 shares | -95% | +57% from low-9% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 12, 2026 | MCLAUGHLIN KEVIN F Director | 7,000 0.01% of outstanding | $309k | Aug 12, 2026 | $230k |
| Aug 3, 2026 | Halpin Michael Officer | 10,000 0.02% of outstanding | $460k | Aug 3, 2026 | $402k |
| Jul 30, 2026 | SIEGAL JONATHAN Officer | 4,500 0.01% of outstanding | $220k | Jul 30, 2026 | $311k |
| Jun 26, 2026 | Flynn Sean C. Officer | 15,000 0.03% of outstanding | $685k | Jun 26, 2026 | $603k |
| Jun 26, 2026 | Hopper Jonathan Mark Officer | 10,000 0.02% of outstanding | $450k | Jun 26, 2026 | $275k |
| Jun 26, 2026 | Mara Joseph Anthony Jr Officer | 5,000 0.01% of outstanding | $224k | Jun 26, 2026 | $203k |
| Jun 26, 2026 | SIEGAL JONATHAN Officer | 2,732 0.01% of outstanding | $123k | Jun 26, 2026 | $188k |
| Jun 18, 2026 | Flynn Sean C. Officer | 15,000 0.03% of outstanding | $603k | Jun 18, 2026 | none |
| Jun 18, 2026 | Halpin Michael Officer | 10,000 0.02% of outstanding | $402k | Jun 18, 2026 | none |
| Jun 2, 2026 | Hopper Jonathan Mark Officer | 4,375 0.01% of outstanding | $153k | Jun 2, 2026 | $122k |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director | 7,000 0.01% of outstanding | $228k | May 13, 2026 | none |
| May 11, 2026 | Wotton Paul K Director | 10,000 0.02% of outstanding | $327k | May 11, 2026 | none |
| May 7, 2026 | Mara Joseph Anthony Jr Officer | 5,000 0.01% of outstanding | $203k | May 7, 2026 | none |
| May 7, 2026 | SIEGAL JONATHAN Officer | 1,422 0.00% of outstanding | $58k | May 7, 2026 | $130k |
| May 6, 2026 | SIEGAL JONATHAN Officer | 3,433 0.01% of outstanding | $130k | May 6, 2026 | none |
| Apr 2, 2026 | Hopper Jonathan Mark Officer | 3,472 0.01% of outstanding | $122k | Apr 2, 2026 | none |
| Mar 23, 2026 | Hagen Heidi Director | 15,000 0.03% of outstanding | $486k | Mar 23, 2026 | none |
| Mar 2, 2026 | Flynn Sean C. Officer | 21,421 0.04% of outstanding | $754k | Mar 2, 2026 | none |
| Mar 2, 2026 | Halpin Michael Officer | 10,305 0.02% of outstanding | $364k | Mar 2, 2026 | none |
| Feb 11, 2026 | MCLAUGHLIN KEVIN F Director | 7,000 0.01% of outstanding | $249k | Feb 11, 2026 | none |
| Jan 7, 2026 | Halpin Michael Officer | 10,000 0.02% of outstanding | $405k | Jan 7, 2026 | $405k |
| Dec 3, 2025 | Wotton Paul K Director | 2,500 0.00% of outstanding | $95k | Dec 3, 2025 | $95k |
| Dec 2, 2025 | Hopper Jonathan Mark Officer | 1,652 0.00% of outstanding | $65k | Dec 2, 2025 | $358k |
| Dec 2, 2025 | Wotton Paul K Director | 2,500 0.00% of outstanding | $95k | Dec 2, 2025 | none |
| Nov 12, 2025 | Halpin Michael Officer | 2,642 0.01% of outstanding | $107k | Nov 11, 2025 | $298k |
Transactions
The newest 50 of 380 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Kevin F McLaughlin director | MOption exercise Common Stock10b5-1 | +7,000 | $13.05 | $91k | 25,300 | Aug 14, 2026 |
| Aug 12, 2026 | Kevin F McLaughlin director | SOpen-market sale Common Stock10b5-1 | -7,000 | $44.53 | $312k | 18,300 | Aug 14, 2026 |
| Aug 12, 2026 | Kevin F McLaughlin director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +7,000 | $0.00 | $0 | 7,000 | Aug 14, 2026 |
| Aug 3, 2026 | Michael Halpin Chief Operating Officer | MOption exercise Common Stock10b5-1 | +10,000 | $16.66 | $167k | 26,394 | Aug 5, 2026 |
| Aug 3, 2026 | Michael Halpin Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $46.84 | $468k | 16,394 | Aug 5, 2026 |
| Aug 3, 2026 | Michael Halpin Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +10,000 | $0.00 | $0 | 26,250 | Aug 5, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Common Stock10b5-1 | +1,500 | $34.90 | $52k | 2,578 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,500 | $48.90 | $73k | 1,078 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Common Stock10b5-1 | +2,500 | $29.82 | $75k | 3,578 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -2,500 | $48.90 | $122k | 1,078 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Common Stock10b5-1 | +500 | $29.82 | $15k | 1,578 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -500 | $48.90 | $24k | 1,078 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +1,500 | $0.00 | $0 | 2,698 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +2,500 | $0.00 | $0 | 4,000 | Jul 31, 2026 |
| Jul 30, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +500 | $0.00 | $0 | 3,500 | Jul 31, 2026 |
| Jun 26, 2026 | Sean C. Flynn Chief Legal Officer | MOption exercise Common Stock10b5-1 | +15,000 | $16.25 | $244k | 16,647 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Common Stock10b5-1 | +5,000 | $29.82 | $149k | 80,753 | Jun 30, 2026 |
| Jun 26, 2026 | Joseph Anthony Mara Jr Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $44.75 | $224k | 16,009 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -232 | $44.90 | $10k | 886 | Jun 30, 2026 |
| Jun 26, 2026 | Sean C. Flynn Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $45.64 | $685k | 1,647 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $45.00 | $225k | 75,753 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Common Stock10b5-1 | +2,500 | $29.82 | $75k | 3,386 | Jun 30, 2026 |
| Jun 26, 2026 | Sean C. Flynn Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +15,000 | $0.00 | $0 | 55,000 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Common Stock10b5-1 | +5,000 | $29.82 | $149k | 80,753 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -2,500 | $44.90 | $112k | 886 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $45.00 | $225k | 75,753 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Siegal Principal Accounting Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +2,500 | $0.00 | $0 | 6,500 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +5,000 | $0.00 | $0 | 25,000 | Jun 30, 2026 |
| Jun 26, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +5,000 | $0.00 | $0 | 20,000 | Jun 30, 2026 |
| Jun 18, 2026 | Michael Halpin Chief Operating Officer | MOption exercise Common Stock10b5-1 | +10,000 | $16.66 | $167k | 26,248 | Jun 22, 2026 |
| Jun 18, 2026 | Sean C. Flynn Chief Legal Officer | MOption exercise Common Stock10b5-1 | +15,000 | $16.25 | $244k | 16,647 | Jun 22, 2026 |
| Jun 18, 2026 | Michael Halpin Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $40.24 | $402k | 16,248 | Jun 22, 2026 |
| Jun 18, 2026 | Sean C. Flynn Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $40.21 | $603k | 1,647 | Jun 22, 2026 |
| Jun 18, 2026 | Sean C. Flynn Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +15,000 | $0.00 | $0 | 70,000 | Jun 22, 2026 |
| Jun 18, 2026 | Michael Halpin Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +10,000 | $0.00 | $0 | 36,250 | Jun 22, 2026 |
| Jun 2, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Common Stock10b5-1 | +4,375 | $16.66 | $73k | 80,128 | Jun 4, 2026 |
| Jun 2, 2026 | Jonathan Mark Hopper Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,375 | $35.00 | $153k | 75,753 | Jun 4, 2026 |
| Jun 2, 2026 | Jonathan Mark Hopper Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +4,375 | $0.00 | $0 | 1,625 | Jun 4, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | MOption exercise Common Stock10b5-1 | +3,500 | $2.63 | $9,205 | 21,800 | May 15, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | SOpen-market sale Common Stock10b5-1 | -3,500 | $32.83 | $115k | 18,300 | May 15, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | MOption exercise Common Stock10b5-1 | +3,500 | $13.05 | $46k | 21,800 | May 15, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | SOpen-market sale Common Stock10b5-1 | -3,500 | $32.82 | $115k | 18,300 | May 15, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +3,500 | $0.00 | $0 | 0 | May 15, 2026 |
| May 13, 2026 | Kevin F McLaughlin director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +3,500 | $0.00 | $0 | 14,000 | May 15, 2026 |
| May 11, 2026 | Paul K Wotton director | SOpen-market sale Common Stock | -2,500 | $33.05 | $83k | 26,302 | May 13, 2026 |
| May 11, 2026 | Paul K Wotton director | SOpen-market sale Common Stock | -7,500 | $32.64 | $245k | 18,802 | May 13, 2026 |
| May 7, 2026 | Joseph Anthony Mara Jr Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $40.50 | $203k | 21,009 | May 8, 2026 |
| May 6, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -3,433 | $38.00 | $130k | 2,540 | May 8, 2026 |
| May 7, 2026 | Jonathan Siegal Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,422 | $40.50 | $58k | 1,118 | May 8, 2026 |
| Apr 29, 2026 | Heidi Hagen director | MOption exercise Common Stock | +3,200 | - | - | 35,050 | May 1, 2026 |
50 of 380 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Dominick ColangeloPresident and CEO
- Sean C. FlynnSVP, General Counsel
- Steven C Gilmandirector
- Heidi Hagendirector
- Michael HalpinChief Operating Officer
- Jonathan Mark HopperChief Medical Officer
- Kevin F McLaughlindirector
- Joseph Anthony Mara JrChief Financial Officer
- Jonathan SiegalPrincipal Accounting Officer
- Paul K Wottondirector
- Robert L Zerbe Mddirector
Questions about VCEL
Answered from the filings on this page, as of the latest one.
Are insiders buying VCEL?
As of Aug 14, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $1.0M by 3 insiders at Vericel Corp in the last 90 days, net -$1.0M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade VCEL on the open market?
Kevin F McLaughlin (director) sold $312k of VCEL on Aug 12, 2026 and filed the Form 4 on Aug 14, 2026. InsiderTell scored 19 (weak), under a 10b5-1 plan, with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Vericel Corp?
11 people have filed a Form 4 at Vericel Corp, among them Dominick Colangelo (President and CEO), Sean C. Flynn (SVP, General Counsel), Steven C Gilman (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.